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Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma
Aims: Fos-related antigen 1 (Fra-1) is a member of the
activator protein 1 (AP-1) transcription factor family.
Our objective was to evaluate the role of Fra-1
expression in breast carcinoma progression and
prognosis.
Methods and results: Fra-1 expression was investigated
by immunohistochemistry in two tissue microarrays
containing, respectively, 85 ductal carcinoma in situ
(DCIS) and 771 invasive ductal carcinoma (IDC)
samples. Staining was observed in the nucleus and
cytoplasm of the carcinomas, but only nuclear staining
was considered to be positive. Fibroblasts associated
with IDC were also Fra-1-positive. The frequency of
Fra-1 positivity in IDC (22.8%) was lower than that in
DCIS (42.2%). No association was found between Fra-1
and clinico-pathological variables in DCIS. In IDC,
Fra-1 expression correlated with aggressive phenotype
markers, including: high grade, oestrogen receptor
negativity and human epidermal growth factor recep-
tor 2 (HER-2) positivity (P = 0.001, 0.015 and 0.004,
respectively), and marginally with the presence of
metastasis (P = 0.07). Fra-1 was more frequently
positive in basal-like (34%) and in HER-2-positive
(38.5%) subtypes than in luminal subtypes. Fra-1
presence did not correlate with survival.
Conclusions: A high frequency of Fra-1 in DCIS tumours
may be associated with early events in breast carcino-
genesis. Although Fra-1 expression correlated with
features of a more aggressive phenotype in IDC, no
relationship with overall survival was found.
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Introduction
Progression of breast cancer is often accompanied by
changes in the pattern of gene expression of neoplastic
cells, resulting in a highly tumorigenic and invasive
cell phenotype. All of these properties are hypothesized
to depend on deregulated transcription.1
The transcription activator protein, activator protein
1 (AP-1), has been broadly implicated in tumour
progression, and many genes involved in cell prolifer-
ation, differentiation, malignant transformation and
cell invasion are AP-1-dependent.2 Fos-related antigen
1 (Fra-1) is a member of the Fos protein family (c-Fos,
Fos B, Fra-1 and Fos-related antigen 2), which are able
to dimerize with members of the Jun family, forming
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AP-1. There are several lines of evidence indicating
that Fra-1 is associated with a more malignant
phenotype and could play a pivotal role in cancer
progression.3 An association between Fra-1 and mes-
enchymal characteristics in highly invasive breast
cancer cells was reported, suggesting that Fra-1 might
be a component of the molecular switch in the
epithelial–mesenchymal transition (EMT), a pro-
gramme by which epithelial cells acquire motility,
invasiveness and resistance to apoptosis.4–10 A poten-
tial role of Fra-1 in the regulation of the expression of
vimentin, a key molecule of EMT, and a requirement
for Fra-1 in motility have been suggested.7,11
The majority of studies concerning the role of Fra-1
in breast cancer have focused on cell culture systems.4–12
Indeed, there are few reports on the expression of Fra-1
in human breast carcinoma samples.13–15 Thus, in the
present work, we attempted to explore the role of Fra-1
in the progression and prognosis of breast cancer, by
undertaking a retrospective immunohistochemical
analysis of Fra-1 expression in a series of ductal
carcinoma in situ (DCIS) and invasive ductal carcinoma
(IDC) samples within tissue microarrays (TMAs), and
performing a comparative analysis of Fra-1 expression
prognostic value with classical prognostic markers and
patient outcome.
Materials and methods
tumour samples and clinical data
Formalin-fixed and paraffin-embedded tissue specimens
from patients with IDC and DCIS diagnosed at the A. C.
Camargo Cancer Hospital (Sa˜o Paulo, Brazil) were
included in this study after approval by the institutional
review board. Because the study was retrospective,
informed patient consent was not required. A TMA
containing 771 samples of primary IDC diagnosed from
1980 to 2005, and an additional TMA containing 85
samples of DCIS lesions [45 associated with an invasive
carcinoma component and 40 without an invasive
component (pure DCIS)] diagnosed from 1980 to 2001,
were produced. The IDC cases studied constituted an
independent cohort and were not paired with the
DCIS ⁄ IDC cases analysed. All cases were reviewed by
C.T.O., M.S. and F.A.S. to corroborate the diagnosis.
The characteristics of these two retrospective cohorts
are given in Table 1. Patients were enrolled according
to the inclusion criteria, consisting of suitable paraffin
blocks for immunohistochemistry, adequate clinical
parameters and follow-up information. The Notting-
ham system was used for assessment of histological
grade of the invasive cases.16 Nuclear grade, based on
the consensus Conference Committee Anonymous,17
was used to classify DCIS cases. In all IDC cases, the
treatment involved mastectomy, radiotherapy and
axillary lymph node dissection. Cases with a positive
immunohistochemical oestrogen receptor (ER) result
received hormone therapy, the others were treated
with chemotherapy. The median follow-up of both
cohorts (IDC and DCIS) was 70 months. At the final
follow-up (July 2007), 367 IDC patients were alive and
404 had died of disease. At the final follow-up of the
DCIS patients (February 2008), 60 patients were alive
and 12 had died. None of the patients with pure DCIS
had experienced recurrence or progression to an
invasive cancer within the median follow-up time.
tma construction
The procedure for construction of TMAs was as
previously described.18 Briefly, cylinders 1 mm in
diameter were punched from selected areas of the
donor paraffin blocks (Beecher Instruments, Silver
Spring, MD, USA). Each case was sampled twice and
distributed in four new blocks, which were stored at
4C, before sections 4 lm thick were prepared for each
marker to be examined by immunohistochemistry.
Normal breast tissue corresponding to a macroscopi-
cally healthy region distinct from neoplastic lesions
were utilized as controls (n = 4).
immunohistochemistry
Monoclonal antibodies against cytokeratin (CK) 5 ⁄ 6
(clone D5 ⁄ 16B4), progesterone receptor (PR) (clone
PgR636) and human epidermal growth factor receptor
2 (HER-2) (polyclonal) were obtained from Dako
(Glostrup, Denmark) and diluted 1:100, 1:200 and
1:1000, respectively. Fra-1 (C12 SC-28310) monoclo-
nal antibody raised against amino acids 1–50 of
human Fra-1 was purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA) and diluted 1:100. Each
slide was also stained with anti-ER (clone 6F-11, 1:50;
Neomarkers, Fremont, CA, USA) and anti-CK14 (clone
LL02, 1:400; BioGenex, Fremont, CA, USA). We
performed optimization, in order to standardise the
immunohistochemical staining for the Fra-1 primary
antibody, concerning antigen retrieval method (equip-
ment for humid heat, pH, and type of buffer), dilution of
primary antibody, and the visualization system meth-
od. After deparaffinisation and rehydration of the TMA
sections, antigen retrieval was performed in a pressure
cooker. After primary antibody incubation and a
polymer–peroxidase (Novocastra, Newcastle, UK)
amplification step, antigen detection was carried out
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in a solution containing 3,3-Diaminobenzidine (Sigma,
St Louis, MO, USA) and 6% H2O2. Counterstaining was
performed with Harris haematoxylin. Positive controls
were included in each staining reaction, and consisted
of breast cancers known to express each of the antigens
of interest. The Fra-1-positive control was a case of
cervical squamous epithelium. An IDC sample was also
used as a positive control. Omission of primary
antibody was used as a negative control in the same
sample. Normal breast could also be interpreted as an
internal negative control in the samples. Specimens
that exhibited a complete absence of staining or £10%
of positive cells were considered to be Fra-1-negative.
An Allred score of ER and PR immunoreactivity £2
was considered to be negative result.19 For HER-2
samples, lack of reactivity in <10% of the tumour cells
was scored as zero. Barely perceptible focal membrane
staining was scored as one. Weak to moderate staining
observed in >10% of the tumour cells was scored as two.
Strong complete membrane staining in >10% of the
tumour cells was scored as three. We considered the
result to be positive only if the score was 3+, according to
American Society of Clinical Oncology of American
Pathologists recommendations.20 For basal CKs (CK5 ⁄ 6
and CK14), the sample was considered to be positive if
‡10% of the tumour cells were reactive. Samples with
immunoreactivity for at least one of the basal CKs
(CK5 ⁄ 6 or CK14) was considered to be CK-positive.
statistical methods
Correlations between antigen expression and other
clinico-pathological parameters were studied with the
chi-square test. Survival probabilities were estimated by
the univariate Kaplan–Meier method and survival
curves were compared with the log rank test (Man-
tel–Haenszel method). ssps version 10.0 for Windows
(SPSS Inc., Chicago, IL, USA) was used for analyses.
Results
The pattern of Fra-1 expression in IDC was purely
nuclear or mixed nuclear and cytoplasmic, but the
reactivity in the latter component was weaker than that
of nuclear staining. Reactivity was scored as positive or
negative according to the frequency of labelled nuclei of
the tumour cells. We reasoned that nuclear localization
of Fra-1 is important for its function as a transcription
factor. The pattern of Fra-1 expression and localization
in DCIS was similar to that in IDC. Fra-1 immunore-
activity was not present in normal breast tissues or in
the breast adenosis cases used as controls. In Figure 1,
we show some representative immunohistochemical
Table 1. Clinicopathological variables in ductal breast carci-
noma patients
Characteristics
In situ (n = 85),
no. (%)
Invasive (n = 771),
no. (%)
Median age,
years (range)
50.5 (20–83) 56 (33–80)
Histology
Comedo 6 (7.1%) Not aplicable
Not comedo 79 (92.9%) Not aplicable
Nodal status
N0 Not aplicable 233 (27.9%)
N+ Not aplicable 533 (62.3%)
Not known Not aplicable 5 (0.6%)
Tumor size
T1 + T2 339 (44.0%)
T3 + T4 432 (56.0%)
Disease stage
TxN0M0 Not aplicable 226 (29.3%)
TxN1M0 Not aplicable 221 (28.7%)
TxN2-3M0 Not aplicable 252 (32.7%)
TxNxM1 Not aplicable 72 (9.3%)
Histological grade
1 11 (12.9%) 99 (12.9%)
2 38 (44.7%) 444 (57.7%)
3 34 (40.0%) 226 (29.4%)
Not known 2 (2.4%) 2 (0.3%)
Status
Alive 60 (83.3%) 367 (47.6%)
Deceased 12 (16.7%) 404 (52.4%)
Oestrogen receptors
Positive 58 (68.2%) 500 (64.9%)
Negative 24 (28.2%) 266 (34.5%)
Not known 3 (3.5%) 5 (0.6%)
Progesterone receptors
Positive 48 (56.5%) 351 (45.5%)
Negative 34 (40.0%) 409 (53.0%)
Not known 3 (3.5%) 11 (1.4%)
HER-2
Positive 34 (40.0%) 105 (13.6%)
Negative 45 (52.9%) 650 (84.3%)
Not known 6 (7.1%) 16 (2.1%)
HER-2, Human epidermal growth factor receptor 2.
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Figure 1. Fos-related antigen 1 (Fra-1) stained by immunohistochemistry in different sections observed at ·400 magnification. A, negative
normal breast. B, negative breast adenosis. C, positive ductal carcinoma in situ. D, strongly positive invasive ductal carcinoma. E, positive control
of cervix and clear negative stroma. F, positive endothelia and fibroblasts in contrast to clear negative stroma.
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reactivity. We obtained reliable immunohistochemical
staining, with a sharp pattern of nuclear staining and a
clear background with no non-specific stromal or
parenchymal staining.
Pure DCIS (n = 40) and DCIS associated with an
invasive component (n = 45) cases were similar with
respect to nuclear grade (non-high grade 57.9% versus
60%, respectively, P = 1.0), ER positivity (71.8%
versus 64.1%, P = 0.63), and PR positivity (61.5%
versus 53.8%, P = 0.65). However, HER-2 frequency
was statistically lower in the DCIS with IDC than in the
pure DCIS cases (30.0% versus 56.4%, P = 0.024).
Table 2 summarizes Fra-1 protein expression in DCIS
and IDC. Fra-1 staining was positive in 22.8% of IDC
cases (176 ⁄ 771), and this percentage was significantly
lower than that observed in DCIS (42.2%, P < 0.001).
Differences in the proportion of Fra-1 positivity between
pure DCIS and those DCIS lesions associated with an
invasive component were not observed. A significantly
higher frequency of HER-2-positive expression in DCIS
than in IDC was also verified (P < 0.001).
The relationships between Fra-1 expression and
clinico-pathological features in DCIS are shown in
Table 3. No significant associations were found be-
tween Fra-1 expression and pathological variables such
as nuclear grade, presence of ER or PR and HER-2
positivity in the DCIS cases.
In contrast, a comparison between Fra-1 expression
and clinico-pathological variables in IDC (Table 4)
revealed an association between Fra-1 positivity and
histological grade 2 or 3 tumours (P = 0.001), lack of
ER expression (P = 0.015) and the presence of HER-2
overexpression (P < 0.004).
Considering the molecular profiles, as previously
defined by Rakha et al.,21 we classified breast carci-
noma samples into subgroups. Lesions were character-
ized as luminal A (HER-2-negative ⁄ ER-positive; 452
cases), luminal B (HER-2-positive ⁄ ER-positive; 38
cases), HER-2 rich (HER-2-positive ⁄ ER-negative ⁄
PR-negative; 65 cases), basal-like (HER-2-negative ⁄
ER-negative ⁄ PR-negative ⁄ CK5 ⁄ 6-positive and ⁄ or CK14-
positive; 47 cases) and triple-negative (HER2-nega-
tive ⁄ ER-negative ⁄ PR-negative but without expression
Table 2. Comparison of Fos-related antigen 1 (Fra-1) and human epidermal growth factor receptor 2 (HER-2) protein
expression between in situ and invasive ductal breast carcinoma
Fra-1 expression HER-2 expression
Negative,
no. (%)
Positive,
no. (%) P-value
Negative,
no. (%)
Positive,
no. (%) P-value
DCIS
Pure 23 (57.5) 17 (42.5) 17 (43.6) 22 (56.4)
With invasive component 26 (57.8) 19 (42.2) <0.001 28 (70.0) 12 (30.0) <0.001
IDC 595 (77.2) 176 (22.8) 650 (86.1) 105 (13.9)
DCIS, Ductal carcinoma in situ; IDC, invasive ductal carcinoma.
Fra-1 expression: negative = no expression to +; positive = ++ to +++. HER-2 expression: negative = no expression to ++;
positive = +++.
P = Statistical significance by chi-square test.
Table 3. Correlation of Fos-related antigen 1 (Fra-1) expres-
sion with prognostic factors in ductal carcinoma in situ
Characteristics
Fra-1 expression
P-value
Negative,
no. (%)
Positive,
no. (%)
Nuclear grade
1 6 (54.5) 5 (45.5) 0.66
2 24 (63.2) 14 (36.8)
3 18 (52.9) 16 (47.1)
Oestrogen receptors
Positive 30 (56.6) 23 (43.4) 0.62
Negative 16 (64.0) 9 (36.0)
Progesterone receptors
Positive 24 (53.3) 21 (46.7) 0.25
Negative 22 (66.7) 11 (33.3)
HER-2
Positive 18 (52.9) 16 (47.1) 0.49
Negative 28 (62.2 17 (37.8)
HER-2, Human epidermal growth factor receptor 2.
P = Statistical significance by chi-square test. A two-sided
P < 0.05 was considered to be statistically significant.
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of CK5 ⁄ 6 and CK14; 134 cases). The frequency of
Fra-1 positivity was significantly different among these
subgroups (P = 0.002): 19% in luminal A cases,
28.9% in luminal B cases, 34% in basal-like cases
and 20.9% in triple-negative cases. The HER-2-positive
group had the highest proportion of tumours positive
for Fra-1 (38.5%) (Table 5).
To determine whether Fra-1 expression was related
to patient survival, we prepared Kaplan–Meier survival
curves and analysed them statistically (log rank test).
Because several clinical parameters are known to affect
survival, we also analysed prognostic indicators.
Survival was found to be reduced in patients with
compromised lymph nodes (P < 0.001), with
ER-negative ⁄ PR-negative tumours or with large
tumours (T3 + T4) (P < 0.001 for both). When patient
survival was stratified by histological grade, differences
in survival were noted between grades (1, 2 and 3,
P = 0.001). Patients with grade 2 (P = 0.02) or grade
3 (P = 0.001) tumours had worse survival than those
with grade 1 tumours. Survival curves showed a poorer
outcome for the HER-2 and triple-negative subgroups
(median survival: 4 and 5 years, respectively) and the
basal-like subgroup (8 years) compared to luminal A
(11 years) or luminal B cases (13 years) (P = 0.002).
When all patients were considered, no differences in
terms of survival were observed between patients with
tumours scored as Fra-1-positive and those with low or
negative levels (P = 0.66) (Table 6).
Discussion
We analysed Fra-1 expression in more than 800 breast
cancers arranged in a TMA. Samples comprised pure
DCIS cases, cases of DCIS within an invasive carci-
noma, and more than 700 cases of IDC. This scenario
enabled us to determine if Fra-1 expression changed
during breast cancer progression. Fra-1 expression was
identified within the nucleus but in some cases,
Table 4. Summary of the relationship between Fos-related
antigen 1 (Fra-1) protein expression and clinico-pathological
features in invasive ductal breast carcinoma
Characteristics
Fra-1 expression
P-value
Negative,
no. (%)
Positive,
no. (%)
Nodal status
N0 179 (76.8) 54 (23.2) 0.852
N+ 413 (77.5) 120 (22.5)
Tumour size
T1 + T2 257 (75.8) 82 (24.2) 0.438
T3 + T4 338 (78.2) 94 (21.8)
Metastases status
M0 493 (76.0) 156 (24.0) 0.077
M1 102 (83.6) 20 (16.4)
Histological grade
1 87 (87.9) 12 (12.1) 0.001
2 349 (78.6) 95 (21.4)
3 158 (69.9) 68 (30.1)
Oestrogen receptors
Positive 399 (79.8) 101 (20.2) 0.015
Negative 191 (71.8) 75 (28.2)
Progesterone receptors
Positive 274 (78.1) 77 (21.9) 0.604
Negative 312 (76.3) 97 (23.7)
HER-2
Positive 69 (65.7) 36 (34.3) 0.004
Negative 514 (79.1) 136 (20.9)
HER-2, Human epidermal growth factor receptor 2.
P = Statistical significance by chi-square test. A two-sided
P < 0.05 was considered to be statistically significant.
Table 5. Distribution of Fos-related antigen 1 (Fra-1) protein
frequency in subtypes of invasive ductal breast carcinoma
Subtype
Total no.
of patients
Positive Fra-1
frequency,
no. (%) P-value
Luminal A 452 86 (19.0) 0.002
Luminal B 38 11 (28.9)
Basal-like 47 16 (34.0)
Triple-negative ⁄
CK-negative
134 28 (20.9)
HER-2 65 25 (38.5)
CK, Cytokeratin; ER, oestrogen receptor; HER-2, human
epidermal growth factor receptor 2; PR, progesterone
receptor.
Luminal A: tumours HER-2-negative ⁄ ER-positive. Luminal B:
tumours HER-2-positive ⁄ ER-positive. Basal-like: triple-nega-
tive and CK5 ⁄ 6-positive or CK14-positive. Triple-negative ⁄
CK-negative: HER-2 ⁄ ER ⁄ PR-negative and CK5 ⁄ 6-negative
and CK14-negative. HER-2: tumours HER-2-positive ⁄
ER-negative and PR-negative.
P = Statistical significance by chi-square test. A two-sided
P < 0.05 was considered to be statistically significant.
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cytoplasmic reactivity was also seen; the latter was
disregarded for analysis. Other studies have previously
described this pattern, but with the use of different
antibodies.13,14
Our results obtained with pure DCIS and invasive
carcinomas show that the frequency of Fra-1 expres-
sion in infiltrative lesions was significantly lower than
in DCIS. Both previous studies investigating Fra-1 by
immunohistochemistry in IDC and DCIS samples found
Fra-1-positive staining in all analysed cases, in dis-
agreement with our data.13,14 The reason for such
differences is uncertain, but may be attributable to
different criteria for positivity and the number of
patients studied.
One might hypothesize that Fra-1 positivity in DCIS
results from a growth response of tumour cells follow-
ing transformation, and is therefore a consequence of
malignancy. No evidence of an association between
Fra-1 expression and prognostic factors in DCIS was
found, implying that a high frequency of Fra-1 expres-
sion may be associated with early events in carcino-
genesis. In accordance with this hypothesis, Chiappetta
et al.14 showed that Fra-1 expression started to become
detectable in fibroadenomas and in breast ductal
hyperplasia. We confirmed their findings,14 as we did
not detect Fra-1 staining in normal breast tissues used
as controls.
We also observed a low frequency of HER-2 expression
in invasive disease as compared to the DCIS cases,
confirming previous reports.22–26 Like that of HER-2,
Fra-1 expression may be characteristic of tumours at
a discrete stage of pathogenesis. The studies of Latta
et al.26 and Pommier et al.27 suggested that HER-2-
negative clones are enriched in the transition to the
invasive state, and invasive abilities may have been
developed in the absence of HER-2 expression. A similar
mechanism might explain the less common expression of
Fra-1 in IDC than in DCIS. However, experimental data
obtained with cells in culture showed that several genes
associated with EMT, such as those encoding metallo-
proteinases, SPARC, vimentin and b1-integrin, were
closely related to Fra-1 expression.4,7,10,11,28,29 Fra-1
transcription and stabilization against proteasome-
dependent degradation is regulated via mitogen-acti-
vated protein kinase–extracellular signal-regulated ki-
nase (ERK1 ⁄ 2),30 and previous studies have supported a
mechanism by which Fra-1 acts downstream of ERK,
inducing EMT and regulating cell migration.28,31,32
A recent study suggested that up-regulation of Fra-
1 in tumour-associated macrophages, which is depen-
dent on the interaction between stroma and breast
tumour cells, may have a pivotal role in tumour
progression.33 The mechanism may be related to
activation of signalling pathways releasing soluble
factors that, in turn, lead to increased production of
angiogenic factors and proteases by tumour cells. We
report here the presence of Fra-1 in fibroblasts
associated with breast cancer, which are considered
to be activated fibroblasts. Thus, epithelial tumor
Table 6. Survival according to pathological and immunohis-
tochemical parameters in invasive ductal breast carcinoma by
univariate analysis
No. of
patients
Median
survival
(years) 95% CI P-value
Patient subgroup
Luminal A 452 11.0 8.66–13.33 0.002
Luminal B 38 13.0 1.18–24.82
Basal-like 47 8.0 1.70–14.29
Triple-negative ⁄
CK-negative
134 5.0 3.34–6.65
HER-2 65 4.0 0.00–9.69
Nodal status
N0 233 Not
reached
– <0.001
N+ 533 6.0 5.02–6.97
Tumour size
T1 + T2 339 Not
reached
– <0.001
T3 + T4 432 4.0 3.37–4.63
Histological grade
1 99 14.0 – 0.001
2 444 9.0 7.13–10.86
3 226 7.0 4.96–9.03
Fra-1 expression
Negative 595 8.0 6.36–9.63 0.66
Positive 176 8.0 4.53–11.46
CI, Confidence interval; CK, cytokeratin; ER, oestrogen
receptor; Fra-1, Fos-related antigen 1; HER-2, human
epidermal growth factor receptor 2; PR, progesterone
receptor.
Luminal A: tumours HER2-negative ⁄ ER-positive. Luminal B:
tumours HER2-positive ⁄ ER-positive. Basal-like: triple-nega-
tive and CK5 ⁄ 6-positive or CK14-positive. Triple-negative ⁄
CK-negative: HER-2 ⁄ ER ⁄ PR-negative and CK5 ⁄ 6-negative
and CK14-negative. HER-2: tumours HER-2-positive ⁄ ER-
negative and PR-negative.
P = Statistical significance by log rank test.
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cells might be influenced by fibroblast in a similar
mechanism.
In IDC, we noted an association of Fra-1 positivity
with poor prognostic characteristics, including ER
negativity, poor differentiation, and overexpression of
HER-2, suggesting an association with aggressive
disease. A negative correlation between Fra-1-positivity
and ER-positive status has been already observed in
breast cancer cell lines and IDC cases.5,7,10,12,34 It
could be that, because of the lack of ER, other factors
form complexes with Fra-1, and that changes in AP-1
composition, activation or nuclear retention may
induce the expression of genes involved in the estab-
lishment of an aggressive phenotype.34,35
Our data indicate a positive association between Fra-
1 and HER-2 in IDC. In agreement with this, one of the
subgroups with the highest percentage of Fra-1 posi-
tivity (38.5%) is characterized by negativity for ER and
PR and the presence of HER-2 overexpression. Thus,
there is a subset of patients in whom HER-2 expression
may be regulated by a pathway involving Fra-1.
In the present study, a higher percentage of Fra-1
expression (34%) was found in basal-like carcinomas
than in the subgroup of luminal tumours. In breast
carcinoma, basal-like and HER-2-positive ⁄ ER-negative
tumour subtypes have been described to be associated
with high expression of the ERK1 ⁄ 2 pathway.36,37 The
presence of Fra-1 in basal-like carcinomas was
expected, as basal-like cultured cells such as MDA-MB
231, BT549, MDA 435S, MX1, BT20 and H5578T
cells have been shown to pre-ferentially express
Fra-1.4,5,10,12,38
In view of our results, we subsequently addressed the
expression of Fra-1 as a prognostic marker in our
cohort of invasive breast cancer patients. Conventional
prognostic factors, such as nodal status, tumour size
and histological grade, and classifying subsets of
patients according to ER, PR and HER-2 immunostain-
ing expression had prognostic value in our study. On
the other hand, in spite of being related to high grade,
ER negativity, the presence of HER-2 and basal
phenotype, Fra-1 expression was not translated into
prognostic significance in terms of survival.
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